治療抵抗性進行がんに、
AMDCプラットフォームから
新たな治療選択肢を創る

A modular antibody-mimetic drug conjugate (AMDC) platform for advanced, treatment-resistant cancers

既存の抗HER2薬などが効かなくなった進行がんには、依然として大きな未充足ニーズ（unmet medical needs）が残されています。 CompleCure の Antibody Mimetic Drug Conjugate (AMDC) は、AIで最適化した抗体ミメティクスを標的認識モジュールに、薬剤モジュールを 非共有結合で「混ぜるだけ」で組み上げるモジュール型ドラッグデリバリー基盤です。

東大発・15年超の計算科学を礎に、リードアセット「Duo-HER2」を前臨床で開発しています。

Duo-HER2 リードアセット（前臨床）

10+ 開発プログラム / 6標的

3件国家プロジェクト採択

3つの柱で、
進行がんの新たな治療選択肢を目指す

従来の ADC は共有結合で薬剤を抗体に結合させるため、DAR（薬物結合比）のばらつきが副作用や効力の不安定さに繋がり得ます。CompleCure の Antibody Mimetic Drug Conjugate (AMDC) は、この構造的課題に非共有結合アセンブリで対処することを目指す設計です。

Theme code	Sub-code	標的 / がん種	ペイロード	次のマイルストーン
CCI-01		HER2 / 乳房外パジェット	光増感剤	前臨床POC拡充・適応探索
CCI-02	01	HER2 / 乳房外パジェット	Duocarmycin	前臨床パッケージ拡充
CCI-02	02 Duo-HER2	HER2 / 進行・転移性乳がん	Duocarmycin	GLP毒性・CMC → IND/CTN申請準備
CCI-02	03	HER2 / 卵巣がん	Duocarmycin＋ATR阻害剤	併用コンセプト前臨床
CCI-02	04	HER2 / 進行胃がん	Duocarmycin	リード最適化
CCI-02	05	HER2 / 大腸・肺がん	Duocarmycin＋抗HER2抗体薬	併用コンセプト検証
CCI-03		CD276 / 膵臓がん等	光増感剤	標的バリデーション
CCI-04		Trop2 / 固形がん	Duocarmycin 光増感剤	モダリティ選定
CCI-05		GPC3 / 肝臓がん	光増感剤	リード探索
CCI-06		CD82 / 血液がん	Duocarmycin 放射性核種(α線)	リード選定

Theme code

Sub-code

標的 / がん種

ペイロード

創薬

前臨床

次のマイルストーン

CCI-01

HER2 / 乳房外パジェット

光増感剤

前臨床POC拡充・適応探索

CCI-02

HER2 / 乳房外パジェット

Duocarmycin

前臨床パッケージ拡充

CCI-02

02 Duo-HER2

HER2 / 進行・転移性乳がん

Duocarmycin

GLP毒性・CMC → IND/CTN申請準備

CCI-02

HER2 / 卵巣がん

Duocarmycin＋ATR阻害剤

併用コンセプト前臨床

CCI-02

HER2 / 進行胃がん

Duocarmycin

リード最適化

CCI-02

HER2 / 大腸・肺がん

Duocarmycin＋抗HER2抗体薬

併用コンセプト検証

CCI-03

CD276 / 膵臓がん等

光増感剤

標的バリデーション

CCI-04

Trop2 / 固形がん

Duocarmycin 光増感剤

モダリティ選定

CCI-05

GPC3 / 肝臓がん

光増感剤

リード探索

CCI-06

CD82 / 血液がん

Duocarmycin 放射性核種(α線)

リード選定

前臨床から臨床へ。
今が最も重要な参画タイミングです。

リードプログラム「Duo-HER2」は AMED 採択・PMDA 相談済みで、前臨床試験が進行中です。 AMDCプラットフォームの技術ライセンス・共同研究・CMC パートナーシップなど、幅広い形での連携をお待ちしています。

社名	株式会社 CompleCure
代表者	代表取締役社長　土屋政幸
所在地	〒151-0053 東京都渋谷区代々木五丁目59番5号
事業内容	モジュール型創薬アーキテクチャーを活用した医薬品研究開発、試薬の提供
コア技術	AMDC プラットフォーム / Cupid-Psyche system / Targeted Combination Therapy™
技術の原点	東京大学先端科学技術研究センター発分子動力学抗体創薬技術研究組合（MDADD）
共同研究先	東京大学、東北大学、千葉大学、琉球大学、福島県立医科大学、星薬科大学ほか

社名

株式会社 CompleCure

代表者

代表取締役社長　土屋政幸

所在地

〒151-0053
東京都渋谷区代々木五丁目59番5号

事業内容

モジュール型創薬アーキテクチャーを活用した医薬品研究開発、試薬の提供

コア技術

AMDC プラットフォーム / Cupid-Psyche system / Targeted Combination Therapy™

技術の原点

東京大学先端科学技術研究センター発
分子動力学抗体創薬技術研究組合（MDADD）

共同研究先

東京大学、東北大学、千葉大学、琉球大学、福島県立医科大学、星薬科大学ほか

Modular Therapeutic Architecture · AMDC

Creating New Treatment Options for Patients with
Treatment-Resistant Advanced Cancers

A modular targeted therapeutics platform designed to address resistance beyond conventional ADCs.

A substantial unmet medical need remains for patients with advanced cancers that no longer respond to existing anti-HER2 agents and other therapies. CompleCure's Antibody Mimetic Drug Conjugate (AMDC) is a modular drug-delivery platform that builds a computationally optimized antibody mimetic as the targeting module together with a payload module through a simple non-covalent "mix-and-go" assembly process.

Built on more than 15 years of computational science research originating at the University of Tokyo, we are advancing our lead development candidate, "Duo-HER2," in Preclinical development.

Snapshot For Investors and Strategic Partners

Duo-HER2 Lead Asset (Preclinical Stage)

10+ Programs Across Multiple Targets and Payload Modalities

3 Backed by Competitive National Grants

Lead Asset Duo-HER2 (CCI-02 series) An AMDC candidate pairing an anti-HER2 antibody mimetic with a Duocarmycin payload

Stage Preclinical (development toward IND/CTN filing) GLP toxicology studies, CMC development, and lead optimization underway

Target indication HER2-positive advanced/metastatic breast cancer Positioned for sequential therapy after existing anti-HER2 agents such as T-DM1 and T-DXd, with room to expand to other tumor types

Key validation Preclinical POC / national project award Tumor regression reported in a preclinical (mouse) model. AMED award secured and PMDA regulatory (development) consultation conducted

CMC partner AGC Inc. Signed a manufacturing process development agreement for a novel AMDC drug; jointly developing the commercial manufacturing process

IP Proprietary and jointly filed patents 10 patents spanning the architecture, payloads, and theranostics, registered or under prosecution in Japan, the U.S., Europe, and China. The trademark "Targeted Combination Therapy" (Reg. No. 6916414) is not included in this count.

Next milestone Complete GLP toxicology and CMC toward IND/CTN filing Aiming to finalize lead optimization and the preclinical package

Fundraising / Use of proceeds Preparing a financing round Primary use of proceeds: (1) GLP toxicology studies, (2) CMC and manufacturing scale-up, (3) completion of lead optimization and preclinical work. We are accelerating development toward clinical entry of the lead asset.

Why Now?

📈

HER2 ADC market >$10B and growing, with no clear successor after T-DXd

⚠️

Growing unmet medical need for patients who progress after T-DXd failure

🔬

Modular platform scalable beyond HER2 across multiple tumor types

💊

Multiple payload modalities (chemo, photo, radio) validated in preclinical models

* The information on this page reflects the status of research and development at the preclinical stage and does not guarantee efficacy, safety, or regulatory approval.

Our Concept

Three Pillars to Create
New Treatment Options for Advanced Cancer

Because conventional ADCs conjugate the drug to the antibody through covalent bonds, variability in the DAR (drug-to-antibody ratio) can contribute to side effects and inconsistent potency. CompleCure's Antibody Mimetic Drug Conjugate (AMDC), a modular targeted therapeutic platform, is designed to address this structural challenge through non-covalent assembly.

An Innovative DDS That Delivers Drugs Precisely on Target

AMDC is a drug-delivery system (DDS) designed to deliver cytotoxic agents selectively to targeted cancer cells. A targeting module that recognizes the cancer antigen and a payload module that carries the therapeutic effect are combined non-covalently and formulated as a complex with a uniform 1:2 DAR. By reducing the quality and manufacturing challenges of conventional ADCs, it delivers a new, next-generation ADC.

Engineered Antibody Mimetics, Designed by AI

We have entered an era in which antibody molecules can be designed and optimized with AI. The AMDC targeting module can incorporate such AI-designed engineered antibody mimetics (VHH antibodies, Affibody molecules, etc.). This removes the need to rely on large, native antibodies as in conventional ADC development, achieving high tumor penetration with a compact ~100 kDa structure and efficiently generating the optimal molecule for each cancer antigen.

Diverse Payloads, Selected to Match the Disease

AMDC allows the therapeutic payload to be freely interchanged. CompleCure is focused on three: (1) the photosensitizer AxSiPc (proprietary, patented), which exerts anti-tumor activity through photoimmunotherapy; (2) Duocarmycin, a potent anticancer agent whose activity is enhanced by inducing synthetic lethality in combination with an ATR inhibitor; and (3) radionuclides that make safer use of well-established radioactive isotopes. By flexibly selecting among them to match each patient's disease, we enable personalized treatment.

CompleCure's technology base traces back to molecular-dynamics simulation research conducted on the K supercomputer at the scale of tens of millions of atoms, under the national project "Molecular Dynamics Antibody Drug Discovery (MDADD)" launched in 2010.

Our proprietary modular drug-discovery platform has been built over more than 15 years through computational-science expertise, the support of rigorous national projects, and a solid patent portfolio.

2010 – 2014

Core Technology Development

Selected for the Cabinet Office's "Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST)." The Molecular Dynamics Antibody Drug Discovery research consortium was established, centered on the Research Center for Advanced Science and Technology (RCAST) at the University of Tokyo, with participation from Osaka University, Chugai Pharmaceutical, and Fujifilm. Ultra-high-precision molecular design, such as "low-immunogenicity streptavidin," was established.
2014 – 2018

Radionuclide Payloads

Successfully developed payload modules using metallic radionuclides (⁶⁴Cu, ¹¹¹In) and the next-generation alpha-emitter ²¹¹At. Core technology leading to theranostics—integrating diagnosis and therapy—was firmly secured by patents.
2019 – 2020

Architecture Established

As the foundational patents on VHH antibodies and Affibody molecules expired, full-scale design of the AMDC (Antibody-Molecule Drug Conjugate) began. Combinatorial manufacturing of diverse VHH and other binders was demonstrated, and a patent network was established covering the modular drug-discovery architecture as well as photosensitizer and anticancer (duocarmycin: Duo) payloads.
2024 – 2028

Acceleration Toward Clinical Development

Following rigorous review, our highest-priority lead program, "Duo-HER2," was selected for the "Smart-Bio Drug Discovery Research Support Program" of AMED (the Japan Agency for Medical Research and Development). Clinical development of the next-generation ADC (AMDC) technology, together with CMC process development (establishing a commercial manufacturing system) through collaboration with global partners such as AGC, is advancing rapidly.

Market

A market shift toward next-generation modalities

As the foundational patents on monoclonal antibodies expire one after another, biosimilar competition is intensifying, and major pharmaceutical companies are shifting development resources toward ADCs and next-generation conjugates. CompleCure has been preparing for this shift for more than 15 years.

Platform

Multiple assets from one platform, with high capital efficiency

Because the targeting module and the payload module can be swapped plug-and-play, the cost of expanding to new targets is contained. From a single platform, we are advancing 6 targets and more than 10 programs, including HER2, CD276, Trop2, and GPC3.

Lead Asset

Duo-HER2 / unmet needs in sequential therapy for advanced breast cancer

A candidate aimed at sequential therapy for patients whose disease no longer responds to existing anti-HER2 agents (T-DM1, T-DXd, etc.). We have confirmed a promising profile in preclinical models and are advancing development that aims to be best in class (preclinical stage). AMED award, PMDA regulatory consultation, and CMC development with AGC are underway.

Partnership & Exit

Parallel paths: out-licensing / co-development / M&A

In addition to out-licensing the lead asset, target-specific licensing or co-development of the AMDC platform itself are options under consideration. With large partnerships and acquisitions active in the ADC field, we are advancing development with multiple exit scenarios in view.

15+ Years of R&D

10+ Development pipelines

3 Competitive National Grants

6 Target antigens

For inquiries about investment or partnership, please feel free to contact us.
We will prepare more detailed materials according to your area of interest.

Contact View the pipeline

Conventional ADC

Covalent
antibody-drug conjugate

Because the drug is chemically conjugated to the antibody, the DAR (drug-to-antibody ratio) varies from molecule to molecule
Requires complex purification, making scale-up difficult
Antibodies (~150 kDa) are large, so penetration into the tumor interior tends to be insufficient
A new antibody and linker must be designed each time the target changes

CompleCure's AMDC

Non-covalent
modular drug discovery

A bis-iminobiotin–streptavidin non-covalent bond consistently achieves a uniform 1:2 DAR
No chemical reaction—assembly completes simply by mixing, greatly simplifying the manufacturing process
A compact ~100 kDa tetrameric structure ensures high tumor penetration
Targeting and payload are independently interchangeable—plug-and-play expansion across many tumor types

Targeting module

Protein

High-specificity VHH / Affibody

Payload module

Chemical compound

Anti-tumor agent / photosensitizer / radionuclide

AMDC

Assembly completed by non-covalent binding

No chemical reaction—just mix

3D structure of the targeting module (low-immunogenicity streptavidin tetramer + VHH/Affibody) — Targeting module

Molecular structure of the anticancer payload module (bis-iminobiotin linker) — Anticancer payload module

3D structure of the completed AMDC (two payloads non-covalently bound to the tetramer) — AMDC

Targeting Module

VHH antibody / Affibody

A low-immunogenicity streptavidin unit is joined to antibody mimetics by linkers, forming a robust tetrameric structure. With four "hands," it reliably captures the target antigen on the cancer-cell surface. At about 100 kDa—smaller than IgG—it achieves high penetration into the tumor interior.

Low-immunogenicity, highly stable tetrameric structure
High tumor penetration (~100 kDa)
Pharmacokinetics distinct from conventional ADCs

Payload Module

Chemo / Photo / Radio

Prepared by chemical synthesis, it can be synthesized and assembled into libraries through a click reaction with a bis-iminobiotin linker. Combined with the targeting module, it expands plug-and-play into diverse modalities.

Anticancer agents (e.g., Duocarmycin) directly damage DNA
Photosensitizers generate singlet oxygen to destroy cells
Radionuclides integrate diagnosis and therapy

A Precisely Defined Binding Ratio

1 : 2 Assembly

The "number" and "location" of payload assembly are strictly defined. For each low-immunogenicity tetramer, two payload modules bind non-covalently and specifically on opposite faces.

Ensures uniform drug delivery
Maximizes reproducibility of therapeutic effect
A defined mode of binding

💊

Anticancer payload module Chemo

Delivers potent agents such as Duocarmycin into cells, directly damaging DNA to kill them.

Chemical structure of the anticancer payload module (Duocarmycin)

☢️

Radionuclide payload module Radio

From diagnosis with ⁶⁴Cu, ¹¹¹In, and ⁸⁹Zn to therapy with ²¹¹At, ²²⁵Ac, and ¹⁷⁷Lu, it enables theranostics.

Chemical structure of the radionuclide payload module

💡

Photosensitizer payload module Photo

A photosensitizer that responds to external light energy generates singlet oxygen to destroy cancer cells.

Chemical structure of the photosensitizer payload module (SiPc)

Core business

AMDC Platform Drug Discovery

Using our modular drug-discovery architecture, we develop next-generation AMDC candidates in house against targets such as HER2, CD276, Trop2, and GPC3. Our highest-priority lead, "Duo-HER2," is being examined preclinically for a differentiated profile against existing anti-HER2 agents such as T-DM1 and T-DXd, targeting a new treatment option for the large unmet medical need of advanced breast cancer after existing therapies. We have completed an AMED award and PMDA regulatory consultation, and CMC development with AGC is underway.

10 Development programs

6 Target antigens

🧪

Ax-SiPc Reagent

We supply research-use reagents based on photosensitizers, supporting R&D at academia and companies.

🔬

Modular Drug-Discovery Architecture

Our proprietary assembly technology links the targeting module and the payload module non-covalently.

🤝

Partner Collaboration & CMC Development

Working with global partners such as AGC Inc., we advance the establishment of a commercial manufacturing system (CMC process).

Theme code	Sub-code	Target / Tumor type	Payload	Next milestone
CCI-01		HER2 / extramammary Paget's disease	Photosensitizer	Expand preclinical POC; explore indications
CCI-02	01	HER2 / extramammary Paget's disease	Duocarmycin	Expand preclinical package
CCI-02	02 Duo-HER2	HER2 / advanced/metastatic breast cancer	Duocarmycin	GLP tox & CMC → prepare IND/CTN filing
CCI-02	03	HER2 / ovarian cancer	Duocarmycin + ATR inhibitor	Preclinical combination concept
CCI-02	04	HER2 / advanced gastric cancer	Duocarmycin	Lead optimization
CCI-02	05	HER2 / colorectal & lung cancer	Duocarmycin + anti-HER2 antibody	Validate combination concept
CCI-03		CD276 / pancreatic cancer, etc.	Photosensitizer	Target validation
CCI-04		Trop2 / solid tumors	Duocarmycin Photosensitizer	Modality selection
CCI-05		GPC3 / liver cancer	Photosensitizer	Lead identification
CCI-06		CD82 / hematologic cancer	Duocarmycin Radionuclide (alpha)	Lead selection

Completed

In progress

* Progress bars and milestones are estimates based on current internal plans and may change as work progresses. Some programs are at stages prior to preclinical.

Partnership & Collaboration

From Preclinical to Clinical.
Now Is the Most Important Time to Get Involved.

Our lead program, "Duo-HER2," has received an AMED award and completed PMDA consultation, and preclinical studies are underway. We welcome collaboration in many forms—technology licensing of the AMDC platform, joint research, CMC partnerships, and more.

2026.03.09 Business

PMDA regulatory (development) consultation conducted for Duo-HER2 as a novel-modality medicinal product

As part of the support under AMED's Smart-Bio Drug Discovery Research Support Program (Principal Investigator: Prof. Motomu Kanai, Graduate School of Pharmaceutical Sciences, the University of Tokyo), we conducted a regulatory (development) consultation with the PMDA for Duo-HER2 as a novel-modality medicinal product. We presented an overview of the consultation item and exchanged views on the development of Duo-HER2.

2025.03.28 Article

CompleCure aims to develop a VHH antibody-drug conjugate without complex linkers for breast cancer

Nikkei Biotechnology — Venture Visit

2024.10.01 Business

"Duo-HER2" selected for AMED's Smart-Bio Drug Discovery Research Support Program

Our highest-priority lead program, "Duo-HER2," was selected following rigorous review for the "Smart-Bio Drug Discovery Research Support Program" of AMED (the Japan Agency for Medical Research and Development), accelerating clinical development of our next-generation ADC (AMDC) technology.

2024.09.24 Press release

Signed an agreement with AGC Inc. on manufacturing process development for a novel AMDC drug

2023.10.13 Press release

Developed a manufacturing method for an antibody-mimetic anticancer-drug conjugate that eliminates enlarged tumors (RCAST, the University of Tokyo)

2022.09.20 Press release

Succeeded in an experiment that completely eliminated recurrent breast cancer (RCAST, the University of Tokyo)

2022.01.26 Press release

Successfully developed a low-burden anticancer drug, a "local antibody-mimetic drug conjugate" (RCAST, the University of Tokyo)

2026.10.19–21 Keynote

Antibody Engineering & Therapeutic Asia 2026 in Kyoto

Speaker: Masayuki Tsuchiya, President & CEO

Talk title: Beyond conventional ADCs — A modular antibody-mimetic drug conjugate platform for flexible cancer targeting

Event details →

2026.09.24–26 Poster

85th Annual Meeting of the Japanese Cancer Association

Kyoto International Conference Center

Two poster presentations: CTO Sugiyama / Senior Researcher Shiratori

Event details →

2026.10.22–24 Poster

64th Annual Meeting of the Japan Society of Clinical Oncology 2026

Kobe International Conference Center

Poster presentation: CTO Sugiyama

Event details →

2025.11.05 Presentation

Dialogue Inc. Webinar "NEXT-GENERATION ANTIBODY-BASED MODALITIES"

Speaker: Masayuki Tsuchiya

Developing and taking on new drug-discovery modalities: a novel complex of biologics and synthetic compounds

Event details →

2025.07.28 Presentation

Nikkei Biotechnology Days — Future Outlook for Drug-Discovery Innovation

From the latest modality trends to new approaches in target discovery

Speaker: Masayuki Tsuchiya

Event details →

2025.06.19 Presentation

25th Annual Meeting of the Protein Science Society of Japan — Luncheon Seminar

Speaker: Masayuki Tsuchiya

Developing and taking on new modalities: a novel complex of biologics and synthetic compounds

Event details →

2025.05.13 Poster

PEGS Boston — Protein & Antibody Engineering Summit

Speaker: Akira Sugiyama

Development of a New ADC Platform Designed by Antibody Mimetic Drug Conjugate

Event details →

2025.04.07 Trademark

Received a trademark registration certificate from the Japan Patent Office

Reg. No. 6916414 "Targeted Combination Therapy"

CEO / President

Masayuki Tsuchiya

Ph.D. (Medicine)

A pioneer of antibody therapeutics. At Chugai Pharmaceutical, he led the world's first cDNA cloning of G-CSF (Neutrogin) and the humanization of an anti-IL-6 receptor antibody (the blockbuster "Actemra"), driving the creation of two in-house drugs. He held positions at the head-of-research level and took part in the management-integration project with Roche. He brings experience spanning exploratory research through regulatory affairs and commercialization.

CTO / Director

Akira Sugiyama

Ph.D.

Has worked at the forefront of AMDC research for 15 years. He oversees R&D of the AMDC platform and has presented results at PEGS Boston, the Japanese Cancer Association, and elsewhere.

CFO / Director

Masanori Nakai

Oversees corporate functions across the board and supports R&D on the administrative side.

Advisors / Scientific advisors

Leading researchers and clinicians in Japan

AMDC's foundational technology was born from years of joint research with researchers who lead Japan in computational science and molecular dynamics. Across drug discovery, chemistry, and clinical medicine, we receive scientific advice from numerous leading researchers and clinicians in Japan.

* Titles and affiliations are current as of the creation of this page.

Message from the CEO

Developing Therapeutics to Cure Advanced Cancer

CompleCure is a drug-discovery startup challenging the innovation of cancer treatment under the vision of "therapeutics aiming for the cure of patients with advanced cancer." Our core technology, the AMDC (Antibody Mimetic Drug Conjugate), was born as the fruit of many years of research together with researchers who lead Japan in advanced computational science and molecular dynamics. Through technology development that leverages supercomputers, we aim to achieve both efficacy and safety beyond conventional therapies and to pioneer the future of cancer treatment.

Our mission is to deliver hope-giving therapies to patients with refractory or advanced cancers and to those for whom existing treatments have stopped working. Drawing on the latest antibody-mimetic technology, we are taking on new therapeutic approaches such as photoimmunotherapy and the induction of synthetic lethality.

Beyond R&D, we actively promote collaboration with partners across the pharmaceutical and medical industries to accelerate the drug-discovery ecosystem. Our manufacturing-technology development with AGC is one example; by bringing together technology and expertise with multiple partners, we aim to deliver treatments to more patients faster.

CompleCure cherishes a spirit of standing close to patients and their families, and we strive to remain an organization that pioneers the future of cancer treatment. Our challenge has only just begun. We sincerely appreciate your continued support and guidance.

Masayuki Tsuchiya, President & CEO

Company name	CompleCure, Inc.
Representative	Masayuki Tsuchiya, President & CEO
Location	5-59-5 Yoyogi, Shibuya-ku, Tokyo 151-0053, Japan
Business	R&D of pharmaceuticals and supply of reagents, leveraging a modular drug-discovery architecture
Core technology	AMDC platform / Cupid-Psyche system / Targeted Combination Therapy™
Technology origin	Born from RCAST, the University of Tokyo Molecular Dynamics Antibody Drug Discovery (MDADD) consortium
Research collaborators	University of Tokyo, Tohoku University, Chiba University, University of the Ryukyus, Fukushima Medical University, Hoshi University, and others

Our Strengths

🧬

15+ years of computational science

Ultra-high-precision molecular design, backed by simulation research at the scale of tens of millions of atoms on the K supercomputer.

🏛️

Support of national projects

Continuously secured support from rigorously reviewed national projects such as FIRST and AMED.

📜

Patent portfolio

A robust patent network spanning the architecture, payloads, and theranostics.

🌐

Global collaboration

Establishing a commercial manufacturing system with partners such as AGC to accelerate clinical development.

AMED awarded Smart-Bio Drug Discovery Research Support Program (2024)

PMDA consultation held Regulatory (development) consultation for Duo-HER2 (2026)

Collaboration with AGC CMC development with a global pharmaceutical partner

🔬

Joint Research & Licensing

Please reach out about technology licensing of the AMDC platform or joint-research agreements with academia and companies. We have a track record of collaboration with several universities, including the University of Tokyo, Tohoku University, and Chiba University.

🤝

VCs, Investors & Business Alliances

We welcome partnerships in many forms—investment in Duo-HER2's preclinical-to-clinical transition, out-licensing or co-development of the AMDC platform, and more. Please feel free to reach out.

🧑‍🔬

Careers & Internships

If you have a background in life sciences, chemistry, or information science, we would love to hear from you. Join us at the frontier of drug discovery toward our goal of "creating new treatment options for advanced cancer."

Please feel free to reach out first via the form.

Go to the contact form →

治療抵抗性進行がんに、AMDCプラットフォームから新たな治療選択肢を創る

当社ステータス

3つの柱で、進行がんの新たな治療選択肢を目指す

薬剤を狙って届ける、革新的なDDS

AIが設計する、人工抗体ミメティクス

病態に合わせて選ぶ、多様なペイロード

AMDC研究開発の系譜と臨床開発へ向けた加速化

基本技術開発

放射性核種ペイロード

アーキテクチャー確立

臨床開発への加速